Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.

Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
Haematologica. 2017 Jul 20;:
Authors: Stivala S, Gobbato S, Infanti L, Reiner MF, Bonetti N, Meyer SC, Camici GG, Lüscher TF, Buser A, Beer JH
Abstract
Amotosalen and ultraviolet A photochemical-based pathogen reduction using the InterceptTM Blood System is an effective and established technology for platelet and plasma components, which is adopted in more than 40 countries worldwide. Several reports point towards a reduced platelet function after Amotosalen/UVA exposure. The current study was undertaken to identify the mechanisms responsible for the early impairment of platelet function by the InterceptTM Blood System. Twenty-five platelet apheresis units were collected from healthy volunteers following standard procedures and split into 2 components, one untreated and the other treated with Amotosalen/UVA. Platelet impedance aggregation in response to collagen and thrombin was reduced by 80% and 60%, respectively, in InterceptTM Blood System-treated units already at day 1 of storage. GpIb levels were significantly lower in Intercept™ Blood System samples and soluble glycocalicin correspondingly augmented; furthermore, GpIb alpha was significantly more desialylated as shown by Erythrina Cristagalli Lecting binding. The pro-apoptotic Bak protein was significantly increased, as well as the MAPK p38 phosphory...

Source: Haematologica - July 20, 2017 Category: Hematology Authors: Stivala S, Gobbato S, Infanti L, Reiner MF, Bonetti N, Meyer SC, Camici GG, Lüscher TF, Buser A, Beer JH Tags: Haematologica Source Type: research